Flipper great posts on this board....in references listed at the bottom of the abstract, note #13 includes Alton Boyton, Chief Scientific Officer at NWBO regarding Phase I Prostate using dendritic cells. It just goes to show how much NWBO has participated in this research over the years.
I posted quite a while back a nice abstract on the advanced cervical cancer study at UPenn with Dr. Coukos and Marnix Bosch, CTO at NWBO which Linda has referenced in her presentations.
I would like to know more about their compassionate use history using DCVax in partnership with a clinic in Israel. Here is just a couple of links showing the interest patients and caregivers have for an alternate treatment when there are no other options available to them. The second link has multiple posts to it but well worth reading through them.
As quite a few have stated on here, we have no way for certainty that DCVax-L and DCVax-Direct will replicate the striking results of their prior trials but the trial design and 6 months progression free survival is a strong possibility. What if the results are striking? NWBO market cap is $150M with only 44M shares outstanding. Look at the MC and OS counts for the similar biotechs and they are well positioned if management continues to execute.
News 
Market Data 
Discover 
